Home LiteratureArticle Details
PMID: 15280408 Published · ppublish English Comparative Study Journal Article

The relation between bone marrow angiogenesis and the proliferation index Ki-67 in multiple myeloma.

Journal of clinical pathology ·Vol. 57 ·No. 8 ·2004-08-00 ·Pages 856-60

Alexandrakis MG, Passam FH, Dambaki C, Pappa CA, Stathopoulos EN

Abstract

Angiogenesis correlates with disease progression in various haematological malignancies. This study investigated the association between microvascular density (MVD) and the Ki-67 proliferation index (Ki-67 PI), bone marrow infiltration, and C reactive protein (CRP) in patients with multiple myeloma. Bone marrow MVD was examined in 44 biopsies at diagnosis and 15 in plateau phase by immunostaining the endothelial cells with a monoclonal antibody to CD34. The Ki-67 PI was evaluated by a double immunostaining technique using the monoclonal antibodies MIB-1 and CD38. MVD, Ki-67 PI, bone marrow infiltration, and CRP were significantly higher in pretreatment patients than in controls and decreased in patients achieving plateau phase. MVD significantly correlated with Ki-67 PI and infiltration, and Ki-67 correlated with infiltration. In multiple myeloma, apart from being a marker of proliferative activity, Ki-67 is also associated with bone marrow angiogenesis and tumour burden.

MeSH Terms
ADP-ribosyl Cyclase/analysis ADP-ribosyl Cyclase 1 Acute Disease Adult Aged Aged, 80 and over Analysis of Variance Antigens, CD/analysis Biomarkers/analysis Bone Marrow Cells/pathology C-Reactive Protein/analysis Cell Division Female Humans Immunohistochemistry/methods Ki-67 Antigen/analysis Male Membrane Glycoproteins Middle Aged Multiple Myeloma/drug therapy,pathology Neovascularization, Pathologic/pathology Prognosis Statistics, Nonparametric
Chemicals
Antigens, CD Biomarkers Ki-67 Antigen Membrane Glycoproteins C-Reactive Protein ADP-ribosyl Cyclase CD38 protein, human ADP-ribosyl Cyclase 1
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Alexandrakis M G
Department of Haematology, University Hospital of Heraklion, PO Box 1352, 71110, Heraklion, Crete, Greece. freda@med.uoc.gr
Passam F H
Dambaki C
Pappa C A
Stathopoulos E N
References (40)
40 references, click to expand
  1. Antitumor activity of thalidomide in refractory multiple myeloma.
    N Engl J Med. 1999 Nov 18;341(21):1565-71 PMID: 10564685
  2. Decrease of bone marrow angiogenesis in myeloma patients achieving a remission after chemotherapy.
    Eur J Haematol. 2001 Apr;66(4):238-44 PMID: 11380603
  3. Prognostic relevance of micro-vessel density in cancer of the urinary bladder.
    Anticancer Res. 1999 Jul-Aug;19(4C):3479-84 PMID: 10629639
  4. Vascular enumeration as a prognosticator for colorectal carcinoma.
    Eur J Cancer. 2000 Jan;36(1):55-60 PMID: 10741295
  5. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia.
    Blood. 2000 Apr 15;95(8):2637-44 PMID: 10753845
  6. The prognostic value of proliferation indices: a study with in vivo bromodeoxyuridine and Ki-67.
    Breast Cancer Res Treat. 2000 Jan;59(2):113-23 PMID: 10817346
  7. Prognostic value of bone marrow angiogenesis in multiple myeloma.
    Clin Cancer Res. 2000 Aug;6(8):3111-6 PMID: 10955791
  8. Relationship between bone marrow angiogenesis and plasma cell infiltration and serum beta2-microglobulin levels in patients with multiple myeloma.
    Ann Hematol. 2001 Oct;80(10):598-601 PMID: 11732871
  9. Angiogenesis in hematologic malignancies.
    Ann Hematol. 2001 Dec;80(12):695-705 PMID: 11797109
  10. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis.
    Clin Cancer Res. 2002 Jul;8(7):2210-6 PMID: 12114422
  11. Bone marrow angiogenesis in multiple myeloma: effect of therapy.
    Br J Haematol. 2002 Dec;119(3):665-71 PMID: 12437642
  12. Inhibition of endothelial cell function in vitro and angiogenesis in vivo by docetaxel (Taxotere): association with impaired repositioning of the microtubule organizing center.
    Mol Cancer Ther. 2002 Nov;1(13):1191-200 PMID: 12479700
  13. Comparison of microvessel density before and after peripheral blood stem cell transplantation in multiple myeloma patients and its clinical implications: multicenter trial.
    Int J Hematol. 2002 Dec;76(5):465-70 PMID: 12512842
  14. The clinical and prognostic significance of erythrocyte sedimentation rate (ESR), serum interleukin-6 (IL-6) and acute phase protein levels in multiple myeloma.
    Clin Lab Haematol. 2003 Feb;25(1):41-6 PMID: 12542441
  15. Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma.
    Ann Hematol. 2003 Jan;82(1):19-23 PMID: 12574959
  16. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival.
    Cancer. 1975 Sep;36(3):842-54 PMID: 1182674
  17. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes).
    J Histochem Cytochem. 1984 Feb;32(2):219-29 PMID: 6198355
  18. Determination of the growth fraction in monoclonal gammopathy with the monoclonal antibody Ki-67.
    Br J Haematol. 1988 Aug;69(4):477-81 PMID: 3044442
  19. Prognostic factors and classification in multiple myeloma.
    Br J Cancer. 1989 Jan;59(1):113-8 PMID: 2757917
  20. Monoclonal antibody Ki-67 as a marker of proliferative activity in monoclonal gammopathies.
    Acta Haematol. 1991;85(1):26-30 PMID: 2011926
  21. The biological and clinical significance of the KI-67 growth fraction in multiple myeloma.
    Hematol Oncol. 1992 Mar-Apr;10(2):125-34 PMID: 1592363
  22. The cell proliferation-associated antigen of antibody Ki-67: a very large, ubiquitous nuclear protein with numerous repeated elements, representing a new kind of cell cycle-maintaining proteins.
    J Cell Biol. 1993 Nov;123(3):513-22 PMID: 8227122
  23. Interleukin-6 in multiple myeloma: correlation with disease activity and Ki-67 proliferation index.
    Leuk Lymphoma. 1994 Jan;12(3-4):265-71 PMID: 8167557
  24. Bone marrow angiogenesis and progression in multiple myeloma.
    Br J Haematol. 1994 Jul;87(3):503-8 PMID: 7527645
  25. Angiogenesis in cancer, vascular, rheumatoid and other disease.
    Nat Med. 1995 Jan;1(1):27-31 PMID: 7584949
  26. Circulating Ki67 positive lymphocytes in multiple myeloma and benign monoclonal gammopathy.
    J Clin Pathol. 1995 Sep;48(9):835-9 PMID: 7490317
  27. Assessment of cell proliferation in normal and pathological bone marrow biopsies: a study using double sequential immunophenotyping on paraffin sections.
    Histopathology. 1995 Nov;27(5):397-405 PMID: 8575729
  28. New perspectives in clinical oncology from angiogenesis research.
    Eur J Cancer. 1996 Dec;32A(14):2534-9 PMID: 9059344
  29. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia.
    Am J Pathol. 1997 Mar;150(3):815-21 PMID: 9060819
  30. Tumour angiogenesis and prognosis.
    Histopathology. 1997 Mar;30(3):294-301 PMID: 9088964
  31. Serum levels of soluble IL-6 receptor in multiple myeloma as indicator of disease activity.
    Acta Haematol. 1997;97(4):191-5 PMID: 9158660
  32. Vascular enumeration as a significant prognosticator for invasive breast carcinoma.
    J Clin Oncol. 1998 May;16(5):1684-8 PMID: 9586879
  33. Antiangiogenic effects of camptothecin analogues 9-amino-20(S)-camptothecin, topotecan, and CPT-11 studied in the mouse cornea model.
    Clin Cancer Res. 1999 Jan;5(1):181-7 PMID: 9918217
  34. Distribution of myeloma plasma cells in peripheral blood and bone marrow correlates with CD56 expression.
    Br J Haematol. 1999 Jan;104(1):138-43 PMID: 10027726
  35. Angiogenesis extent and macrophage density increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphomas.
    Br J Cancer. 1999 Feb;79(5-6):965-70 PMID: 10070898
  36. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes.
    Blood. 2000 Sep 15;96(6):2240-5 PMID: 10979972
  37. Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma.
    Ann Hematol. 2000 Oct;79(10):574-7 PMID: 11100749
  38. Immunohistochemical expression of the p53, p21/Waf-1, Rb, p16 and Ki67 proteins in multiple myeloma.
    Anticancer Res. 2000 Nov-Dec;20(6B):4619-25 PMID: 11205312
  39. Increased vascularization in myeloma.
    Eur J Haematol. 2001 Feb;66(2):89-93 PMID: 11168515
  40. Angiogenesis in myelodysplastic syndromes.
    Br J Cancer. 1999 Dec;81(8):1398-401 PMID: 10604739
Article Info
Journal
Journal of clinical pathology
Abbr.
J Clin Pathol
ISSN
0021-9746
DOI
10.1136/jcp.2003.013110
Email
freda@med.uoc.gr
Published
2004-08-00
Pages
856-60
Language
English
Region
England
NLM ID
0376601
PMCID
PMC1770397
Subset
IM
External Links
PubMed source DOI: 10.1136/jcp.2003.013110 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2